Congenica Tries To Bring Clarity To Personalized Medicine For Rare Diseases
Medtech Insight spoke to David Atkins, the CEO of genomics company Congenica, to learn more about how its platform is being used in one of the largest genetics studies to date. The company expects the technology to eventually transform treatment of rare diseases.
You may also be interested in...
In this roundup feature focusing on developments in digital health, Medtech Insight highlights interviews with Medtronic, Abbott and Congenica, partnerships and launches, and AI and cybersecurity announcements from November.
Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.
Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership
DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.